Bharat Parenterals Limited

BSE:541096 Stock Report

Market Cap: ₹11.0b

Bharat Parenterals Valuation

Is 541096 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 541096 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 541096 (₹1679.65) is trading above our estimate of fair value (₹18.38)

Significantly Below Fair Value: 541096 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 541096?

Key metric: As 541096 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 541096. This is calculated by dividing 541096's market cap by their current revenue.
What is 541096's PS Ratio?
PS Ratio3.7x
Sales₹2.94b
Market Cap₹10.96b

Price to Sales Ratio vs Peers

How does 541096's PS Ratio compare to its peers?

The above table shows the PS ratio for 541096 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2.1x
524280 Kopran
1.7xn/a₹10.7b
506260 Anuh Pharma
1.6xn/a₹10.2b
531633 Lincoln Pharmaceuticals
2.1xn/a₹12.7b
524774 NGL Fine-Chem
3xn/a₹11.3b
541096 Bharat Parenterals
3.7xn/a₹11.0b

Price-To-Sales vs Peers: 541096 is expensive based on its Price-To-Sales Ratio (3.7x) compared to the peer average (2.1x).

Price to Sales Ratio vs Industry

How does 541096's PS Ratio compare vs other companies in the IN Pharmaceuticals Industry?

13 CompaniesPrice / SalesEstimated GrowthMarket Cap
NECLIFE Nectar Lifesciences
0.4xn/aUS$87.67m
539561 Remedium Lifecare
0.07xn/aUS$26.84m
532637 Mangalam Drugs & Organics
0.5xn/aUS$20.05m
524412 Aarey Drugs & Pharmaceuticals
0.3xn/aUS$19.21m
541096 3.7xIndustry Avg. 3.1xNo. of Companies18PS02.44.87.29.612+
13 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 541096 is expensive based on its Price-To-Sales Ratio (3.7x) compared to the Indian Pharmaceuticals industry average (3.1x).

Price to Sales Ratio vs Fair Ratio

What is 541096's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

541096 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3.7x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 541096's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Vivimed Labs

₹410.4m

Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India.

VIVIMEDLAB

₹4.95

7D

0%

1Y

-45.9%

Sanofi India

₹142.5b

Manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally.

SANOFI

₹6,197.45

7D

0.8%

1Y

-23.0%

Novartis India

₹26.1b

Operates as a healthcare company in India.

500672

₹1,058.30

7D

3.5%

1Y

52.4%